Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER_GOV 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 12Non-Muscle Invasive Bladder Neoplasms 4Carcinoma, Transitional Cell 2Ureteral Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Kidney Neoplasms 1Hematuria 1Carcinoma in Situ 1

Interventions

pembrolizumab 44Gemcitabine 23enfortumab vedotin 21Nivolumab 20Cisplatin 17avelumab 16Magnetic Resonance Spectroscopy 15Carboplatin 14atezolizumab 13Specimen Handling 12Docetaxel 11sacituzumab govitecan 9Paclitaxel 8Ipilimumab 8durvalumab 6Mitomycin 5Fluorodeoxyglucose F18 5cabozantinib 4Taxes 4toripalimab 3pemigatinib 3erdafitinib 3X-Rays 3Radiosurgery 3Platinum 3Pemetrexed 3Immunoglobulin G 3CTLA-4 Antigen 3Biopsy 3ALT-803 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Cystoscopy × 1 year × Clear all
NCT07037589 2025-11-21

BLUSH

Vastra Gotaland Region

Recruiting
300 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Hematuria, Kidney Neoplasms

NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

National Cancer Institute (NCI)

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡